Provider fact sheet · dataset v2026.08.14-4 · last touched —

Remedy Meds: GLP-1 programs, prices, and verification status (2026)

Quick take

Remedy Meds is a unverified entry in our universe. Forbes Health's August 2026 'customer support' pick among affordable tirzepatide providers (4.3 stars in their system).

Programs and pricing, in plain sentences

Compounded tirzepatide, all-inclusive — status: third-party reported. $399/mo flat across doses (Forbes, U.S. News, and Peptide Dossier corroborated, Apr–Aug 2026); semaglutide $299; microdose tier $189 published pre-quiz; brand Zepbound ~$1,399. Unlimited visits/messaging bundled; billing-complaint pattern reported at BBB.

Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.

Update — August 14, 2026: Upgraded to third-party reported with unusually strong corroboration: Forbes Health, U.S. News, and a July industry review all state $399/mo flat compounded tirzepatide and $299 semaglutide — no membership, no dose upcharges, unlimited provider visits and messaging bundled, 49 states via 503A partners. A separately captured $189/mo microdose tier is the only price published pre-quiz. Reported friction: a C-range BBB profile with recurring-billing complaints against a 4.6 Trustpilot; brand Zepbound available at ~$1,399. The value proposition is the support model, not the price — it is the most expensive compounded program we track.

Verification status and open items

Current status: unverified, last touched —. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: universe scan. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.

How Remedy Meds fits the market

Forbes Health's August 2026 'customer support' pick among affordable tirzepatide providers (4.3 stars in their system). Our own verification of pricing, pharmacy, and terms is incomplete, so Remedy holds watchlist status with the Forbes citation logged as a reported signal, not a conclusion. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.

Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.